Evidence map›Paper›PMID 40755755›Full record

ArticleFrontiers in immunology2025

Identification of clinically relevant profiles in colorectal cancer through integrated analysis of bacterial DNA and metabolome in serum.

Juan Vicente-Valor, Sofía Tesolato, Dulcenombre Gómez-Garre, Mateo Paz-Cabezas, Adriana Ortega-Hernández, Constanza Fernández-Hernández, Sofía de la Serna, Inmaculada Domínguez-Serrano, Jana Dziakova, Daniel Rivera and 4 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Juan Vicente-Valor *Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University, Madrid, Spain.
Sofía Tesolato *Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University, Madrid, Spain.
Dulcenombre Gómez-GarreSan Carlos Health Research Institute (IdISSC), San Carlos Hospital, Madrid, Spain.
Mateo Paz-CabezasSan Carlos Health Research Institute (IdISSC), San Carlos Hospital, Madrid, Spain.
Adriana Ortega-HernándezSan Carlos Health Research Institute (IdISSC), San Carlos Hospital, Madrid, Spain.
Constanza Fernández-HernándezCentre for Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, Universidad San Pablo CEU, CEU Universities, Madrid, Spain.
Sofía de la SernaSan Carlos Health Research Institute (IdISSC), San Carlos Hospital, Madrid, Spain.
Inmaculada Domínguez-SerranoSan Carlos Health Research Institute (IdISSC), San Carlos Hospital, Madrid, Spain.
Jana DziakovaSan Carlos Health Research Institute (IdISSC), San Carlos Hospital, Madrid, Spain.
Daniel RiveraSan Carlos Health Research Institute (IdISSC), San Carlos Hospital, Madrid, Spain.
Francisco-Javier RupérezCentre for Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, Universidad San Pablo CEU, CEU Universities, Madrid, Spain.
Antonia GarcíaCentre for Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, Universidad San Pablo CEU, CEU Universities, Madrid, Spain.
Antonio TorresSan Carlos Health Research Institute (IdISSC), San Carlos Hospital, Madrid, Spain.
Pilar IniestaDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There is increasing evidence demonstrating the relationship between microbiota and colorectal cancer. Several studies have been published analyzing microbiota in tissues and feces from cancer patients; however, there are only a few publications investigating the clinical utility of serum microbiome from colorectal cancer patients. Our aim was to advance in the search for serum biomarkers for the diagnosis of colorectal cancer. Methods: We conducted a cross-sectional study assessing bacterial DNA and metabolomic profiles in 64 serum samples from subjects affected by colorectal cancer and controls. A metagenomic analysis of the bacterial 16S rRNA gene in serum was established, and serum metabolites were detected through an untargeted metabolic study based on Gas Chromatography-Quadruple Time-Of-Flight Mass Spectrometry with accurate mass. Results and Discussion: After integrating the data resulting from the bioinformatics and statistical analyses, we obtained different profiles in colorectal cancer population and controls, regardless of the subjects' age, gender and body mass index. Serum levels of Firmicutes and threonic acid were the most relevant characteristics that could help differentiate both groups, achieving an excellent predictive accuracy in this discovery cohort (area under the ROC curve = 0.95). Although these results should be validated in other cohorts through multicenter studies, we consider that our data could be relevant and applicable to the early diagnosis of colorectal cancer.

Indexed as

Biomarkers, TumorColorectal NeoplasmsDNA, BacterialMetabolomeAdultAgedBacteriaCross-Sectional StudiesFemaleGastrointestinal MicrobiomeHumansMaleMetabolomicsMiddle AgedRNA, Ribosomal, 16SBiomarkers, TumorDNA, BacterialRNA, Ribosomal, 16Sbacterial DNAcolorectal cancerdiagnosismetabolomeserum biomarkers

Identifiers

PMID40755755
PMCPMC12314883

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.